Objective
to determine if the beneficial effects of transcatheter mitral valve repair (TMVR) persisted between 24 to 36 months following initial revascularisation of patients treated with TMVR and guideline-directed medical therapy (GDMT) compared to GDMT alone
Study
open-label, multicentre randomised study
Population
mitral regurgitation (moderate-to-severe or severe) and heart failure secondary to LV-dysfunction
Endpoints
heart failure hospitalisations (HFHs) during 36 months follow-up
Conclusion
TMVR persisted to reduce heart failure hospitalisations compared to medical treatment in symptomatic patients with moderate to severe mitral regurgitation through 36 months
Mack et al. J Am Coll Cardiol. 2021;77:1029-40
